Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

(2013) M. A. Nauck et al.   DIABETOLOGIA

Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human

(2012) Jun Wu et al.   CELL

Recent advances in incretin-based therapies

(2012) David Russell-Jones et al.   CLINICAL ENDOCRINOLOGY

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat

(2012) A. Bénardeau et al.   DIABETES OBESITY & METABOLISM

An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

(2012) Krystal L. Edwards et al.   Diabetes Technology & Therapeutics

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21

(2012) Timo D. Müller et al.   JOURNAL OF PEPTIDE SCIENCE

Targeted estrogen delivery reverses the metabolic syndrome

(2012) Brian Finan et al.   NATURE MEDICINE

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis

(2012) Su-Jin Kim et al.   PLoS One

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

(2011) N. Mentis et al.   DIABETES

Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

(2011) Emilie Faivre et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

GLP-1 and energy balance: an integrated model of short-term and long-term control

(2011) Jason G. Barrera et al.   Nature Reviews Endocrinology

Glucose Intolerance and Reduced Proliferation of Pancreatic  -Cells in Transgenic Pigs With Impaired Glucose-Dependent Insulinotropic Polypeptide Function

(2010) S. Renner et al.   DIABETES

Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo

(2010) S. Uhles et al.   DIABETES OBESITY & METABOLISM

GIP increases human adipocyte LPL expression through CREB and TORC2-mediatedtrans-activation of theLPLgene

(2010) Su-Jin Kim et al.   JOURNAL OF LIPID RESEARCH

Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action

(2010) Jonathan W. Day et al.   JOURNAL OF PEPTIDE SCIENCE

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

(2010) Scott B. Widenmaier et al.   PLoS One

GIP: No Longer the Neglected Incretin Twin?

(2010) R. N. Kulkarni   Science Translational Medicine

Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

(2009) C. W. Chia et al.   DIABETES

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

(2008) Matthew C. Althage et al.   JOURNAL OF BIOLOGICAL CHEMISTRY